Alexis Borisy
CIK 1319446 · Executive Chairman · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FMI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
245 FIRST STREET, 16TH FLOOR
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RVMD | Director | 2,340,075 | $186.25 | $435.85M | $0 | 6 | 2026-06-23 |
| PBLS | Director | 105,414 | $26.88 | $2.83M | $0 | 2 | 2026-06-15 |
| RLAY | Director | 234,175 | $18.64 | $4.37M | $0 | 10 | 2026-06-10 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 74,160 | $129.46 | $9.60M | -$2.01M | 18 | 2025-07-21 |
| RVMDW | Director | 2,338,884 | $9.42 | $22.03M | $0 | 3 | 2025-06-30 |
| TNGX | Director | 17,500 | $23.12 | $404.7K | $0 | 4 | 2025-06-09 |
| EQRx, Inc. (EQRXW) Delisted | Executive Chairman | 0 | $0.05 | $0 | $0 | 3 | 2023-11-09 |
| OPK | Director | 312,612 | $1.61 | $504.9K | $0 | 4 | 2023-06-23 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Director | 256 | $11.19 | $2.9K | $0 | 5 | 2021-09-23 |
| Foundation Medicine, Inc. (FMI) Delisted | Director | 6,642,818 | — | — | -$23.82M | 7 | 2017-06-22 |
| EDIT | Director | 0 | $2.54 | $0 | $0 | 2 | 2017-06-19 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | CEO & President | 312,204 | — | — | -$3.3K | 6 | 2009-01-28 |
Recent Filings · Page 7 of 8
71 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-06-22 | Foundation Medicine, Inc. (FMI) Delisted | Grant (A) | +5,997 | $193.3K | EDGAR |
| 2015-05-15 | Foundation Medicine, Inc. (FMI) Delisted | Other (J) | +448 | $0 | EDGAR |
| 2015-04-16 | Foundation Medicine, Inc. (FMI) Delisted | Sell (S) | −241,768 | -$12.09M | EDGAR |
| 2015-04-09 | Foundation Medicine, Inc. (FMI) Delisted | Sell (S) | −234,542 | -$11.73M | EDGAR |
| 2013-10-02 | Foundation Medicine, Inc. (FMI) Delisted | Conv (C) | +6,219,645 | $0 | EDGAR |
| 2009-01-28 | EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | Sell (S) | −5,256 | -$3.3K | EDGAR |
| 2008-07-17 | EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-01-29 | EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | Tax (F) | −3,969 | -$20.4K | EDGAR |
| 2008-01-17 | EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2007-07-13 | EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.